Free Trial
NASDAQ:OBIO

Orchestra BioMed Q3 2024 Earnings Report

Orchestra BioMed logo
$2.71 +0.11 (+4.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.70 -0.01 (-0.41%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Orchestra BioMed EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.99 million
Expected Revenue
$0.81 million
Beat/Miss
Beat by +$180.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Orchestra BioMed's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 3:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Orchestra BioMed Earnings Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat